There are also ILs that may mainly act as anti-steatotic, anti-inflammatory and/or anti-fibrotic for the onset and progression of MASLD, including IL-10, IL-22, IL-25, and IL-27. This evidence concerns the gene IL22 and metabolic dysfunction-associated steatotic liver disease.